**CLAIMS**

1. A pharmaceutical composition comprising:

(a) 50 IU/ml to ~~2500~~2000 IU/ml of a long-acting chimeric Factor VIII-Fc (rFVIIIFc) polypeptide;

(b) 11.7 mg/ml to 14.63 mg/ml sucrose;

(c) 10.8 mg/ml to 13.2 mg/ml sodium chloride (NaCl);

(d) 0.927 mg/ml to 1.133 mg/mL L-histidine;

(e) 5 mM to 10 mM calcium chloride; and

(f) 0.117 mg/ml to 0.143 mg/ml polysorbate 20 or polysorbate 80,

wherein the long-acting rFVIIIFc polypeptide comprises a first subunit and a second subunit, wherein the first subunit comprises an amino acid sequence at least 95% identical to amino acids 20 to 1684 of SEQ ID NO: 2, and wherein the second subunit comprises at least a first neonatal Fc receptor (FcRn) binding partner, wherein first FcRn binding partner comprises an amino acid sequence at least 95% identical to amino acids 21 to 247 of SEQ ID NO: 4.

2. The pharmaceutical composition of claim 1, comprising about 13.3 mg/ml sucrose.

3. The pharmaceutical composition of claim 1 or claim 2, comprising about 12.0 mg/ml NaCl.

4. The pharmaceutical composition of any one of claims 1 to 3, comprising about 1.03 mg/ml L-histidine.

5. The pharmaceutical composition of any one of claims 1 to 4, comprising about 0.13 mg/ml polysorbate 20 or polysorbate 80.

6. The pharmaceutical composition of any one of claims 1 to 5, comprising about 83 IU/ml, about 167 IU/ml, about 250 IU/ml, about 333 IU/ml, about 500 IU/ml, about 667 IU/ml, about 1000 IU/ml, about 1333 IU/ml, about 1667 IU/ml, or about 2000 IU/ml of the rFVIIIFc polypeptide.

7. The pharmaceutical composition of any one of claims 1 to 6, comprising:

(a) about 83 IU/ml, about 167 IU/ml, about 250 IU/ml, about 333 IU/ml, about 500 IU/ml, about 667 IU/ml, about 1000 IU/ml, about 1333 IU/ml, about 1667 IU/ml, or about 2000 IU/ml of the rFVIIIFc polypeptide;

(b) about 13.3 mg/ml sucrose;

(c) about 12.0 mg/ml NaCl;

(d) about 1.03 mg/ml L-histidine;

(e) about 5.4 mM calcium chloride; and

(f) about 0.13 mg/ml polysorbate 20 or polysorbate 80.

8. The pharmaceutical composition of any one of claims 1 to 7, comprising polysorbate 20.

9. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is packaged in a pharmaceutical kit, wherein the kit comprises:

(a) a first container comprising a lyophilized powder, wherein the powder comprises

(i) about 250 IU, about 500 IU, about 750 IU, about 1000 IU, about 1500 IU, about 2000 IU, about 3000 IU, about 4000 IU, about 5000 IU, or about 6000 IU of the rFVIIIFc polypeptide;

(ii) about 40 mg sucrose;

(iii) about 36 mg sodium chloride;

(iv) about 3.1 mg L-histidine;

(v) about 2.40 mg calcium chloride dihydrate; and

(vi) about 0.40 mg polysorbate 20 or polysorbate 80; and

(b) a second container comprising sterilized water for injection at a volume sufficient to produce, when combined with the lyophilized powder of the first container, a solution comprising:

(a) about 83 IU/ml, about 167 IU/ml, about 250 IU/ml, about 333 IU/ml, about 500 IU/ml, about 667 IU/ml, about 1000 IU/ml, about 1333 IU/ml, about 1667 IU/ml, or about 2000 IU/ml of the rFVIIIFc polypeptide;

(b) about 13.3 mg/ml sucrose;

(c) about 12.0 mg/ml NaCl;

(d) about 1.03 mg/ml L-histidine;

(e) about 5.4 mM calcium chloride; and

(f) about 0.13 mg/ml polysorbate 20 or polysorbate 80.

10. The pharmaceutical composition of claim 9, wherein the lyophilized powder comprises about 250 IU, about 500 IU, about 750 IU, about 1000 IU, about 1500 IU, about 2000 IU, or about 3000 IU of the rFVIIIFc polypeptide, and wherein the solution comprises about 83 IU/ml, about 167 IU/ml, about 250 IU/ml, about 333 IU/ml, about 500 IU/ml, about 667 IU/ml, or about 1000 IU/ml of the rFVIIIFc polypeptide, respectively.

11. The pharmaceutical composition of claim 9 or claim 10, wherein the first container is a glass vial comprising a rubber stopper.

12. The pharmaceutical composition of any one of claims 9 to 11, wherein the second container is a syringe body, and wherein the syringe body is associated with a plunger.

13. The pharmaceutical composition of any one of claims 9 to 12, comprising polysorbate 20.

14. The pharmaceutical composition of any one of claims 1 to 13, wherein the first subunit comprises amino acids 20 to 1683 of SEQ ID NO: 2, and the second subunit comprises amino acids 21 to 246 of SEQ ID NO: 4.